BIOGEN IDEC MA INC.
🏢 View company profile →216Patents
145Active
216Granted
53Portfolio score
Filing activity: May 25, 1995 → Mar 26, 2014 · 104 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7863419B2 | Antibodies having altered effector function and methods for making the same | Chemistry; Metallurgy | 117 | Active |
| US8399514B2 | Treatment for multiple sclerosis | Physics | 80 | Active |
| US9034324B2 | Anti-BCMA antibodies | Chemistry; Metallurgy | 70 | Active |
| US7829092B2 | Recombinant anti-VLA4 antibody molecules | Chemistry; Metallurgy | 53 | Active |
| US8226950B2 | Recombinant anti-VLA4 antibody molecules | Chemistry; Metallurgy | 49 | Active |
| US6875846B2 | Heterologous polypeptide of the TNF family | Human Necessities | 42 | Expired |
| US8147829B2 | Anti-IGR-1R antibodies and uses thereof | Chemistry; Metallurgy | 37 | Active |
| US8058406B2 | Composition comprising antibodies to LINGO or fragments thereof | Chemistry; Metallurgy | 37 | Active |
| US7465449B2 | Anti-αvβ6 antibodies | Physics | 33 | Expired |
| US8551476B2 | SP35 antibodies and uses thereof | Chemistry; Metallurgy | 33 | Active |
| US6869605B2 | BAFF, inhibitors thereof and their use in the modulation of B-cell response | Human Necessities | 32 | Expired |
| US8425910B2 | Composition comprising antibodies to LINGO or fragments thereof | Chemistry; Metallurgy | 32 | Active |
| US7358054B2 | Antibodies to VLA-1 | Emerging Cross-Sectional Technologies | 30 | Expired |
| US7951918B2 | Stabilized polypeptide compositions | Emerging Cross-Sectional Technologies | 30 | Active |
| US7033589B1 | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | Chemistry; Metallurgy | 28 | Expired |
| USD660418S1 | Limiter for dispensing device | General | 25 | Expired |
| US8784823B2 | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof | Chemistry; Metallurgy | 25 | Active |
| US7700097B2 | Purification and preferential synthesis of binding molecules | Chemistry; Metallurgy | 25 | Expired |
| US8293237B2 | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof | Chemistry; Metallurgy | 24 | Active |
| US7001598B2 | Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents | Emerging Cross-Sectional Technologies | 24 | Expired |
| US8293923B2 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | Chemistry; Metallurgy | 23 | Active |
| US7767687B2 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors | Chemistry; Metallurgy | 23 | Active |
| US8642040B2 | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists | Chemistry; Metallurgy | 23 | Active |
| US7838639B2 | Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor | Physics | 22 | Active |
| US7465705B2 | Nogo receptor antagonists | Emerging Cross-Sectional Technologies | 22 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.